Paxil Regulatory Litigation May Affect Exclusivity, FDA “Ministerial” Role
Executive Summary
Ivax' declaratory judgment actions against Paxil maker GlaxoSmithKline could threaten Apotex' 180-day exclusivity on paroxetine
You may also be interested in...
FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
Paxil Generic Exclusivity To Be Shared By At Least Four Firms; Suits Continue
Ivax is one of at least four drug companies that will share exclusivity for generic versions of GlaxoSmithKline's Paxil (paroxetine)
Paxil Generic Exclusivity To Be Shared By At Least Four Firms; Suits Continue
Ivax is one of at least four drug companies that will share exclusivity for generic versions of GlaxoSmithKline's Paxil (paroxetine)